Primary data · sourced from public filings·700+ Indian companies · India-first·
Open screener
Home / Reports / Healthtech
Healthtech · January 2026

Hospital SaaS and AI-assisted diagnostics lead India's healthtech fundability as ABDM adoption crosses 500 million health IDs in January 2026

Indian healthtech startups averaged FCI 57 on AletheiaAI in January 2026. Hospital SaaS, ABDM-native health data platforms, and AI-assisted radiology scored highest. Pharmacy delivery and teleconsultation aggregators continued to face structural headwinds.

Period
January 2026
Sector
Healthtech
Top Theme
Hospital SaaS & ABDM-native diagnostics

India Healthtech Sector: January 2026 Snapshot

Healthtech saw 18 pitch decks reviewed on AletheiaAI in January 2026, with an average FCI of 57. ABDM crossing 500 million health IDs created new data-access opportunities for ABDM-native plays.

What Investors Are Rewarding

Hospital SaaS — HMIS, revenue cycle management, and patient flow optimisation for 50-300 bed hospitals — averaged FCI 65. India's 80,000+ fragmented hospital market is a greenfield for SaaS.

ABDM-native health data platforms — clinical decision support, chronic care management, and referral management built on the Unified Health Interface — averaged FCI 63. ABDM's 500M health ID milestone validated adoption.

AI-assisted radiology — X-ray reading, CT scan analysis, and pathology slide scoring for resource-constrained hospitals — averaged FCI 62.

Where Decks Are Failing

Pharmacy delivery averaged FCI 40. Tata 1mg, PharmEasy, and Reliance's NetMeds have determined the category. No new wedge for entrants.

D2C wellness supplements averaged FCI 43. Category is perceived as brand-building, not SaaS — angel investors in tech don't price in CPG economics.

Notable Trends

  1. Preventive health for corporates — B2B preventive health platforms targeting corporate ESG mandates averaged FCI 62.
  2. Mental health B2B — SaaS for corporate Employee Assistance Programmes averaged FCI 60.
  3. Medical device SaaS — Remote patient monitoring for wearable medical devices averaged FCI 61.

Investor Sentiment

INVEST/PASS: 32%/68%. Regulatory pathway (CDSCO clearance for SaMD) was the top diligence question for clinical-grade products.

Entities Referenced in This Report
NHAABDMAyushman BharatCDSCOICMRPractoApollo HospitalsManipal Hospitals1mgmFine

Frequently Asked Questions

Share this report

Tracking this sector?

Get the daily India market brief

Read today’s brief